We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Plexus (PLXS) Down 4.2% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Plexus (PLXS - Free Report) . Shares have lost about 4.2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Plexus due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Plexus Q3 Earnings Top Estimates
Plexus reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.45, down 0.7% year over year. The figure outpaced the Zacks Consensus Estimate of $1.28 per share.
Revenues of $961 million decreased 6% year over year. The top-line contraction was due to poor performance in the Healthcare/Life Sciences and Industrial sectors. Revenues missed the Zacks Consensus Estimate by 1.95%.
In the reported quarter, revenues from the Asia-Pacific and America declined 8.7% and 10.5%, respectively. Revenues from Europe, the Middle East and Africa rose 30.5%.
During the fiscal third quarter, Plexus won 35 manufacturing programs, which are estimated to contribute $279 million in annualized revenues once fully ramped into production.
Market Sector Details
Industrial revenues were down 5.8% year over year to $403 million, contributing 42% to total revenues.
Healthcare/Life Sciences’ revenues declined 15.7% from the year-ago quarter’s levels to $380 million, contributing 40% to total revenues.
Revenues from Aerospace/Defense increased 24.5% year over year to $178 million, contributing 18% to total revenues.
The company’s top 10 customers accounted for 48% of net revenues in the fiscal third quarter.
Operating Details
Gross profit on a GAAP basis increased 0.8% year over year to $94.4 million.
Selling and administrative expenses increased 8.5% from the year-ago quarter to $45.9 million.
Plexus reported an adjusted operating income of $55.6 million, up 1% year over year. Adjusted operating margin expanded 90 basis points sequentially to 5.8%.
Balance Sheet & Cash Flow
As of Jun 29, 2024, Plexus had cash & cash equivalents worth $269.8 million compared with $252.9 million as of Jul 1, 2023.
As of Jun 30, 2024, Plexus had long-term debt and finance lease obligations, net of the current portion of $90.7 million compared with $187.5 million as of Jul 1, 2023.
In the quarter under review, the cash flow from operations was $131.6 million. Plexus reported a free cash outflow of $114.2 million.
The company repurchased $18.6 million of its shares at an average price of $100.64 per share under its repurchase program. This leaves shares worth $19.5 million available under the existing $50 million authorization.
Outlook
For fourth-quarter fiscal 2024, revenues are projected to be between $990 million and $1.03 billion.
GAAP operating margin is expected to be between 4.6% and 5%. GAAP EPS is expected to be in the band of $1.14-$1.29.
Adjusted EPS is expected in the range of $1.5-$1.65.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
VGM Scores
Currently, Plexus has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Plexus has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Plexus (PLXS) Down 4.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Plexus (PLXS - Free Report) . Shares have lost about 4.2% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Plexus due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Plexus Q3 Earnings Top Estimates
Plexus reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.45, down 0.7% year over year. The figure outpaced the Zacks Consensus Estimate of $1.28 per share.
Revenues of $961 million decreased 6% year over year. The top-line contraction was due to poor performance in the Healthcare/Life Sciences and Industrial sectors. Revenues missed the Zacks Consensus Estimate by 1.95%.
In the reported quarter, revenues from the Asia-Pacific and America declined 8.7% and 10.5%, respectively. Revenues from Europe, the Middle East and Africa rose 30.5%.
During the fiscal third quarter, Plexus won 35 manufacturing programs, which are estimated to contribute $279 million in annualized revenues once fully ramped into production.
Market Sector Details
Industrial revenues were down 5.8% year over year to $403 million, contributing 42% to total revenues.
Healthcare/Life Sciences’ revenues declined 15.7% from the year-ago quarter’s levels to $380 million, contributing 40% to total revenues.
Revenues from Aerospace/Defense increased 24.5% year over year to $178 million, contributing 18% to total revenues.
The company’s top 10 customers accounted for 48% of net revenues in the fiscal third quarter.
Operating Details
Gross profit on a GAAP basis increased 0.8% year over year to $94.4 million.
Selling and administrative expenses increased 8.5% from the year-ago quarter to $45.9 million.
Plexus reported an adjusted operating income of $55.6 million, up 1% year over year. Adjusted operating margin expanded 90 basis points sequentially to 5.8%.
Balance Sheet & Cash Flow
As of Jun 29, 2024, Plexus had cash & cash equivalents worth $269.8 million compared with $252.9 million as of Jul 1, 2023.
As of Jun 30, 2024, Plexus had long-term debt and finance lease obligations, net of the current portion of $90.7 million compared with $187.5 million as of Jul 1, 2023.
In the quarter under review, the cash flow from operations was $131.6 million. Plexus reported a free cash outflow of $114.2 million.
The company repurchased $18.6 million of its shares at an average price of $100.64 per share under its repurchase program. This leaves shares worth $19.5 million available under the existing $50 million authorization.
Outlook
For fourth-quarter fiscal 2024, revenues are projected to be between $990 million and $1.03 billion.
GAAP operating margin is expected to be between 4.6% and 5%. GAAP EPS is expected to be in the band of $1.14-$1.29.
Adjusted EPS is expected in the range of $1.5-$1.65.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month.
VGM Scores
Currently, Plexus has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Plexus has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.